Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,287 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05993299 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | completed | Phase 2 | 7 | USWM, LLC (dba US WorldMeds)INDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY |
| 7 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT06183489 | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma(ERASMM) | active not recruiting | Phase 2 | 50 | European Myeloma Network B.V.NETWORK | 4 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | recruiting | Phase 3 | 448 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 18 | Sep 2, 2026 | clinicaltrials |
| NCT06761937 | Thermotherapy for Locally Advanced Head and Neck Cancer(TANCA-I) | active not recruiting | Phase 1 | 2 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | recruiting | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07354074 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | recruiting | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07485569 | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial(REPOTHYROID-II) | active not recruiting | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07690618 | Thermotherapy for Head and Neck Cancer Patients(TANCAP-I) | recruiting | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799298 | Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)(SPLENDID RCT) | not yet recruiting | N/A | 360 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04008706 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients(ASSURE) | completed | Phase 3 | 552 | AstraZenecaINDUSTRY | 17 | Sep 1, 2026 | clinicaltrials |
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 277 | Daiichi SankyoINDUSTRY | 16 | Sep 1, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT05990582 | The Alkmaar MLPTI Cohort Study: Outcomes at 9 Years | completed | N/A | 153 | Noordwest ZiekenhuisgroepOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 875 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 12 | Sep 1, 2026 | clinicaltrials |
| NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) | recruiting | Phase 1 / Phase 2 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT07636148 | Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance(PreciseOnco) | recruiting | — | 2,000 | Mark C Burgmans, MD PhDOTHER | 2 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04751786 | Dose Escalation Study of Immunomodulatory Nanoparticles(PRECIOUS-01) | active not recruiting | Phase 1 | 15 | Radboud University Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06212817 | Dietary Fiber Before Colorectal Cancer Surgery | completed | N/A | 54 | Wageningen UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07077161 | Cabozantinib Dose Skipping as an Alternative to Dose Reductions(SKIPPY 2) | recruiting | Phase 2 | 34 | dr. Tom van der HulleOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04170283 | A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib | active not recruiting | Phase 3 | 955 | BeOne MedicinesINDUSTRY | 18 | Aug 28, 2026 | clinicaltrials |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)(DG-03) | active not recruiting | Phase 2 | 452 | AstraZenecaINDUSTRY | 14 | Aug 28, 2026 | clinicaltrials |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | active not recruiting | Phase 1 | 498 | Genentech, Inc.INDUSTRY | 17 | Aug 28, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005) | active not recruiting | Phase 3 | 710 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Aug 28, 2026 | clinicaltrials |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | active not recruiting | Phase 3 | 686 | Merck Sharp & Dohme LLCINDUSTRY | 32 | Aug 28, 2026 | clinicaltrials |
| NCT06637423 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)(TroFuse-027) | recruiting | Phase 1 / Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 28, 2026 | clinicaltrials |
| NCT07680556 | Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma(PRIMER) | recruiting | N/A | 30 | Radboud University Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)(PELFIRE) | recruiting | — | 27 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | active not recruiting | Phase 3 | 586 | Daiichi SankyoINDUSTRY | 21 | Aug 27, 2026 | clinicaltrials |
| NCT05391295 | Mapping Emotional Dynamics During Corticosteroid Treatment | completed | — | 15 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06130553 | A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors(PRIMROSE) | recruiting | Phase 1 / Phase 2 | 334 | AstraZenecaINDUSTRY | 8 | Aug 27, 2026 | clinicaltrials |
| NCT07117214 | A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers | recruiting | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 533 | Acerta Pharma BVINDUSTRY | 15 | Aug 26, 2026 | clinicaltrials |
| NCT03048084 | Seizure Treatment in Glioma(STING) | recruiting | Phase 4 | 120 | Leiden University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03133546 | Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M(BOOSTER) | completed | Phase 2 | 155 | ETOP IBCSG Partners FoundationNETWORK | 6 | Aug 26, 2026 | clinicaltrials |
| NCT03448042 | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | active not recruiting | Phase 1 | 123 | Genentech, Inc.INDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
| NCT05328908 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer(RELATIVITY-123) | terminated | Phase 3 | 769 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection(REZILIENT4) | active not recruiting | Phase 3 | 360 | Taiho Oncology, Inc.INDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer(RAINFOL-05) | recruiting | Phase 2 | 240 | GenmabINDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials